Showing 2501-2510 of 3039 results for "".
- Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at ARVOhttps://modernod.com/news/kala-pharmaceuticals-to-present-clinical-data-for-kpi-012-its-mesenchymal-stem-cell-secretome-product-for-the-treatment-of-pced-at-arvo/2480824/Kala Pharmaceuticals reported clinical data from a phase 1b trial of KPI-012, its novel, cell-free secretome therapy for the treatment of severe ocular diseases driven by impaired healing. As previously disclosed, treatment with KPI-012 was well tolerated and resulted in significant improvements
- Opthea Presenting Clinical Data at ARVO 2022 Annual Meetinghttps://modernod.com/news/opthea-presenting-clinical-data-at-arvo-2022-annual-meeting/2480820/Opthea announced the presentation of novel clinical data at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2022 conference, taking place in Denver, Colorado from May 1-4, 2022 and virtually from May 11-12, 2022. Jason Slakter, MD, of
- Alcon Introduces Virtual Reality Surgical Training Technologyhttps://modernod.com/news/alcon-introduces-virtual-reality-surgical-training-technology/2480761/Alcon announced the launch of the Alcon Fidelis Virtual Reality (VR) Ophthalmic Surgical Simulator, a portable VR tool for cataract surgeons-in-training. As part of the Alcon Experience Academy, the VR simulator of
- Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI Surgical System in Pseudophakic Eyes with Open-Angle Glaucomahttps://modernod.com/news/sight-sciences-announces-first-patient-treated-in-trident-european-trial-to-evaluate-the-omni-surgical-system-in-pseudophakic-eyes-with-open-angle-glaucoma/2480722/Sight Sciences announced that the first patient has been treated in the novel TRIDENT clinical trial, designed to demonstrate the OMNI Surgical System with higher volume as a safe and effective standalone treatment option, compared to implantation of iStent inject (Glaukos), in
- Genentech Presents Longer-Term Efficacy and Safety for Enspryng in NMOSDhttps://modernod.com/news/genentech-presents-longer-term-efficacy-and-safety-for-enspryng-in-nmosd/2480720/Genentech is presenting a range of new data from its neuroscience portfolio at the AAN 2022 Annual Meeting (April 2-7 in Seattle), including
- LumiThera Announces US LIGHTSITE III Clinical Trial Meets Primary Efficacy Endpoint in Improving Vision in Dry AMD Patientshttps://modernod.com/news/lumithera-announces-us-lightsite-iii-clinical-trial-meets-primary-efficacy-endpoint-in-improving-vision-in-dry-amd-patients/2480712/LumiThera announced positive findings in its LIGHTSITE III multicenter clinical trial in non-neovascular (dry) age-related macular degeneration (AMD) subjects treated with the Valeda Light Delivery System. LIGHTSITE III, a prospective, double-masked, randomized, multicenter clinica
- EssilorLuxottica and CooperCompanies Finalize Joint Venturehttps://modernod.com/news/essilorluxottica-and-coopercompanies-finalize-joint-venture/2480705/EssilorLuxottica and CooperCompanies have announced the finalization of their joint venture agreement for SightGlass Vision. This collaboration accelerates the commercialization of novel spectacle lens technologies to expand the myopia management category. SightGlass Vision’s Diffusion
- Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink Therapyhttps://modernod.com/news/glaukos-announces-commencement-of-phase-2-corneal-health-clinical-program-for-third-generation-ilink-therapy/2480696/Glaukos announced that it has commenced a phase 2 clinical program for its third-generation iLink therapy designed to treat keratoconus. Glaukos’ iLink pharmaceutical platform consists of novel single-use drug formulations that are bio-activa
- Théa Completes its Acquisition of Akorn’s Branded Ophthalmic Productshttps://modernod.com/news/thea-completes-its-acquisition-of-akorns-branded-ophthalmic-products/2480688/Théa Pharma announced the completion of its previously announced acquisition of seven branded ophthalmic products from Akorn. The transaction expands Théa’s eye care portfolio in the United States. Financial terms of the deal were not disclosed. &
- LumiThera Completes Acquisition of Diopsyshttps://modernod.com/news/lumithera-completes-acquisition-of-diopsys/2480675/LumiThera announced the completion of its acquisition of Diopsys, a provider of modern visual electrophysiology medical devices. Diopsys is now a wholly owned subsidiary of LumiThera. Financial terms the transaction were not disclosed. EyewireTV's covereage of the acq